BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598-610. [PMID: 18781911 DOI: 10.2174/138920008785821710] [Cited by in Crossref: 219] [Cited by in F6Publishing: 207] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 Lin HL, Zhang H, Kenaan C, Hollenberg PF. Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition. Drug Metab Dispos 2016;44:1771-9. [PMID: 27538916 DOI: 10.1124/dmd.116.071662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Russo G, Paganotti GM, Soeria-Atmadja S, Haverkamp M, Ramogola-Masire D, Vullo V, Gustafsson LL. Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments. Infect Genet Evol 2016;37:192-207. [PMID: 26602158 DOI: 10.1016/j.meegid.2015.11.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
3 Wei Y, Li L, Zhou X, Zhang QY, Dunbar A, Liu F, Kluetzman K, Yang W, Ding X. Generation and characterization of a novel Cyp2a(4/5)bgs-null mouse model. Drug Metab Dispos 2013;41:132-40. [PMID: 23073733 DOI: 10.1124/dmd.112.048736] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
4 Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, Walder B, Gabay C, Nissen MJ, Desmeules JA, Hannouche D, Samer CF. Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clin Pharmacol Ther 2021;109:1668-76. [PMID: 33341941 DOI: 10.1002/cpt.2146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Li H, Chen T, Cottrell J, Wang H. Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 2009;37:1098-106. [PMID: 19196842 DOI: 10.1124/dmd.108.026005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
6 Hashemi-Soteh MB, Hosseini E, Fazelnia S, Ghasemian-Sorbeni F, Madahian S, Shiran MR. Frequencies of CYP2B64,5, and 6 Alleles within an Iranian Population (Mazandaran). Genet Res (Camb) 2021;2021:8703812. [PMID: 34949964 DOI: 10.1155/2021/8703812] [Reference Citation Analysis]
7 Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM. Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology. Front Pharmacol 2020;11:1184. [PMID: 32848787 DOI: 10.3389/fphar.2020.01184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 2016;6:413-25. [PMID: 27709010 DOI: 10.1016/j.apsb.2016.07.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
9 Tompkins L, Lynch C, Haidar S, Polli J, Wang H. Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res 2010;27:1703-12. [PMID: 20503067 DOI: 10.1007/s11095-010-0170-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
10 Grangeon A, Gravel S, Gaudette F, Turgeon J, Michaud V. Highly sensitive LC–MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. Journal of Chromatography B 2017;1040:144-58. [DOI: 10.1016/j.jchromb.2016.12.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
11 Kwon YJ, Shin S, Chun YJ. Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Arch Pharm Res 2021;44:63-83. [PMID: 33484438 DOI: 10.1007/s12272-021-01306-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, Ellingrod VL, Kamali M, McInnis M, Sun D. Identification of non-reported bupropion metabolites in human plasma. Biopharm Drug Dispos 2016;37:550-60. [PMID: 27723114 DOI: 10.1002/bdd.2046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
13 Coelho AV, Silva SP, de Alencar LC, Stocco G, Crovella S, Brandão LA, Guimarães RL. ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients: The Journal of Clinical Pharmacology. The Journal of Clinical Pharmacology 2013;53:1286-93. [DOI: 10.1002/jcph.165] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kojima M, Degawa M. Sex differences in constitutive mRNA levels of CYP2B22, CYP2C33, CYP2C49, CYP3A22, CYP3A29 and CYP3A46 in the pig liver: Comparison between Meishan and Landrace pigs. Drug Metabolism and Pharmacokinetics 2016;31:185-92. [DOI: 10.1016/j.dmpk.2016.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
15 Thomford NE, Awortwe C, Dzobo K, Adu F, Chopera D, Wonkam A, Skelton M, Blackhurst D, Dandara C. Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. Molecules 2016;21:E211. [PMID: 26891286 DOI: 10.3390/molecules21020211] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
16 Li L, Zhang QY, Ding X. A CYP2B6-humanized mouse model and its potential applications. Drug Metab Pharmacokinet 2018;33:2-8. [PMID: 29402634 DOI: 10.1016/j.dmpk.2018.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Radulović NS, Filipović SI, Zlatković DB, Đorđević MR, Stojanović NM, Randjelović PJ, Mitić KV, Jevtović-stoimenov TM, Ranđelović VN. Immunomodulatory pinguisane-type sesquiterpenes from the liverwort Porella cordaeana (Porellaceae): the “new old” furanopinguisanol and its oxidation product exert mutually different effects on rat splenocytes. RSC Adv 2016;6:41847-60. [DOI: 10.1039/c6ra04308a] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
18 Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. Clin Pharmacokinet 2017;56:355-69. [PMID: 27641153 DOI: 10.1007/s40262-016-0456-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
19 Zakaria Z, Badhan RKS. The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy. Eur J Pharm Sci 2018;119:90-101. [PMID: 29635009 DOI: 10.1016/j.ejps.2018.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S. Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population. Drug Metab Dispos 2009;37:1991-3. [DOI: 10.1124/dmd.109.027755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, Daali Y. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. Basic Clin Pharmacol Toxicol 2016;119:284-90. [PMID: 27009433 DOI: 10.1111/bcpt.12586] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mayumi K, Hanioka N, Masuda K, Koeda A, Naito S, Miyata A, Narimatsu S. Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions. Biochem Pharmacol 2013;85:1182-94. [PMID: 23395694 DOI: 10.1016/j.bcp.2013.01.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 Maldonado-rojas W, Rivera-julio K, Olivero-verbel J, Aga DS. Mechanisms of interaction between persistent organic pollutants (POPs) and CYP2B6: An in silico approach. Chemosphere 2016;159:113-25. [DOI: 10.1016/j.chemosphere.2016.05.049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010;38:1218-29. [PMID: 20335270 DOI: 10.1124/dmd.109.031393] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 9.5] [Reference Citation Analysis]
25 Tralau T, Luch A. The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications. Expert Opinion on Drug Metabolism & Toxicology 2013;9:1541-54. [DOI: 10.1517/17425255.2013.828692] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
26 Xu C, Quinney SK, Guo Y, Hall SD, Li L, Desta Z. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos 2013;41:2004-11. [PMID: 23846872 DOI: 10.1124/dmd.113.051755] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
27 Takeshita A, Igarashi-migitaka J, Koibuchi N, Takeuchi Y. Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. Journal of Endocrinology 2013;216:297-305. [DOI: 10.1530/joe-12-0297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
28 Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg PF. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab Dispos 2013;41:1813-24. [PMID: 23886699 DOI: 10.1124/dmd.113.053108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
29 Ipe J, Li R, Metzger IF, Bo Li Lu J, Gufford BT, Desta Z, Liu Y, Skaar TC. Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity. Clin Pharmacol Ther 2021;109:485-93. [PMID: 32772362 DOI: 10.1002/cpt.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Ahmed S, Khan S, Janjua K, Imran I, Khan AU. Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population. Mol Genet Genomic Med 2021;9:e1527. [PMID: 33599403 DOI: 10.1002/mgg3.1527] [Reference Citation Analysis]
31 Stashi E, York B, O'Malley BW. Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol Metab 2014;25:337-47. [PMID: 24953190 DOI: 10.1016/j.tem.2014.05.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
32 Wei Y, Wu H, Li L, Liu Z, Zhou X, Zhang QY, Weng Y, D'Agostino J, Ling G, Zhang X, Kluetzman K, Yao Y, Ding X. Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. Drug Metab Dispos 2012;40:1144-50. [PMID: 22397853 DOI: 10.1124/dmd.112.044826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
33 Wang PF, Neiner A, Lane TR, Zorn KM, Ekins S, Kharasch ED. Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches. Mol Pharm 2019;16:898-906. [PMID: 30589555 DOI: 10.1021/acs.molpharmaceut.8b01214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
34 Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2014;24:133-8. [PMID: 24401834 DOI: 10.1097/FPC.0000000000000019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Tucci JD, Pumuye PP, Helsby NA, Barratt DT, Pokeya PP, Hombhanje F, Somogyi AA. Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenet Genomics 2018;28:153-64. [PMID: 29768302 DOI: 10.1097/FPC.0000000000000335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
36 Weber A, Szalai R, Sipeky C, Magyari L, Melegh M, Jaromi L, Matyas P, Duga B, Kovesdi E, Hadzsiev K, Melegh B. Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples. Pharmacological Reports 2015;67:460-4. [DOI: 10.1016/j.pharep.2014.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
37 Marwa KJ, Schmidt T, Sjögren M, Minzi OM, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J 2014;13:420. [PMID: 25363545 DOI: 10.1186/1475-2875-13-420] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
38 Lim Y, Cheng C, Chen W, Chang S, Hung D, Chen J, Wan L, Ma W, Lin Y, Chen C, Yokoi T, Nakajima M, Chen C. Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity. Arch Toxicol 2015;89:57-72. [DOI: 10.1007/s00204-014-1230-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
39 Chen C, Liu J, Halpert JR, Wilderman PR. Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes. Biochemistry 2018;57:817-26. [PMID: 29215266 DOI: 10.1021/acs.biochem.7b01024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Li L, Bao X, Zhang QY, Negishi M, Ding X. Role of CYP2B in Phenobarbital-Induced Hepatocyte Proliferation in Mice. Drug Metab Dispos 2017;45:977-81. [PMID: 28546505 DOI: 10.1124/dmd.117.076406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Liu J, Lu YF, Corton JC, Klaassen CD. Expression of cytochrome P450 isozyme transcripts and activities in human livers. Xenobiotica 2021;51:279-86. [PMID: 33350342 DOI: 10.1080/00498254.2020.1867929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metab Pharmacokinet 2016;31:107-16. [PMID: 27053325 DOI: 10.1016/j.dmpk.2015.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
43 Varshney E, Saha N, Tandon M, Shrivastava V, Ali S. Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus 2012;1:34. [PMID: 23961363 DOI: 10.1186/2193-1801-1-34] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
44 Xuan J, Chen S, Ning B, Tolleson WH, Guo L. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact 2016;255:63-73. [PMID: 26477383 DOI: 10.1016/j.cbi.2015.10.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
45 Roy PP, Roy K. Pharmacophore mapping, molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors. Molecular Simulation 2010;36:887-905. [DOI: 10.1080/08927022.2010.492834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
46 Aceti A, Gianserra L, Lambiase L, Pennica A, Teti E. Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virology 2015; 4(3): 198-208 [PMID: 26279982 DOI: 10.5501/wjv.v4.i3.198] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
47 Tomas Ž, Kuhanec A, Škarić-Jurić T, Petranović MZ, Narančić NS, Janićijević B, Salihović MP. Distinctiveness of the Roma population within CYP2B6 worldwide variation. Pharmacogenomics 2017;18:1575-87. [PMID: 29095103 DOI: 10.2217/pgs-2017-0105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Wilderman PR, Gay SC, Jang HH, Zhang Q, Stout CD, Halpert JR. Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme. FEBS J 2012;279:1607-20. [PMID: 22051155 DOI: 10.1111/j.1742-4658.2011.08411.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
49 Chan CYS, Roberts O, Rajoli RKR, Liptrott NJ, Siccardi M, Almond L, Owen A. Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. Drug Metab Pharmacokinet 2018;33:179-87. [PMID: 29921509 DOI: 10.1016/j.dmpk.2018.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. [PMID: 23467454 DOI: 10.3389/fgene.2013.00024] [Cited by in Crossref: 178] [Cited by in F6Publishing: 136] [Article Influence: 19.8] [Reference Citation Analysis]
51 Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O. Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics. Basic Clin Pharmacol Toxicol 2018;123:42-50. [DOI: 10.1111/bcpt.13004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
52 Amunugama HT, Zhang H, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme. Drug Metab Dispos 2012;40:1765-70. [PMID: 22685215 DOI: 10.1124/dmd.112.045971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
53 Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metab Dispos 2016;44:948-58. [PMID: 26608082 DOI: 10.1124/dmd.115.067546] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
54 Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Adv Pharmacol 2018;83:3-32. [PMID: 29801580 DOI: 10.1016/bs.apha.2018.04.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
55 Halpert JR. Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 2011;39:1113-21. [PMID: 21502194 DOI: 10.1124/dmd.111.039719] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wang C, Chen C, Wang S, Wu S. Cation-selective exhaustive injection and sweeping micellar electrokinetic chromatography for the analysis of methadone and its metabolites in serum of heroin addicts. Journal of Chromatography A 2011;1218:6832-7. [DOI: 10.1016/j.chroma.2011.07.086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
57 Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther 2011;338:803-9. [PMID: 21659470 DOI: 10.1124/jpet.111.183111] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
58 Eyer F, Roberts DM, Buckley NA, Eddleston M, Thiermann H, Worek F, Eyer P. Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochem Pharmacol 2009;78:531-7. [PMID: 19433070 DOI: 10.1016/j.bcp.2009.05.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
59 Koh KH, Jurkovic S, Yang K, Choi SY, Jung JW, Kim KP, Zhang W, Jeong H. Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy. Biochem Pharmacol 2012;84:93-103. [PMID: 22484313 DOI: 10.1016/j.bcp.2012.03.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
60 Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res (Camb) 2018;7:664-80. [PMID: 30090613 DOI: 10.1039/c7tx00326a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
61 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 27.4] [Reference Citation Analysis]
62 Palacharla RC, Nirogi R, Uthukam V, Manoharan A, Ponnamaneni RK, Kalaikadhiban I. Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims. Xenobiotica 2018;48:663-75. [PMID: 28737446 DOI: 10.1080/00498254.2017.1354267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
63 Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 2010;20:520-3. [PMID: 20648701 DOI: 10.1097/fpc.0b013e32833947c2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
64 Penell J, Lind L, Fall T, Syvänen AC, Axelsson T, Lundmark P, Morris AP, Lindgren C, Mahajan A, Salihovic S, van Bavel B, Ingelsson E, Lind PM. Genetic variation in the CYP2B6 gene is related to circulating 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) concentrations: an observational population-based study. Environ Health 2014;13:34. [PMID: 24885815 DOI: 10.1186/1476-069X-13-34] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
65 Huang HX, Wu H, Zhao Y, Zhou T, Ai X, Dong Y, Zhang Y, Lai Y. Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. Xenobiotica 2021;51:616-23. [PMID: 33509019 DOI: 10.1080/00498254.2021.1880670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Zhou X, Gao Y, Hu J, Dong Y, Zhang H, Lai Y. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. Eur J Clin Pharmacol 2018;74:37-44. [DOI: 10.1007/s00228-017-2346-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
67 Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM; ANRS12154 Study Group. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother 2013;57:2154-60. [PMID: 23459477 DOI: 10.1128/AAC.02294-12] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
68 Shmarakov IO, Lee YJ, Jiang H, Blaner WS. Constitutive androstane receptor mediates PCB-induced disruption of retinoid homeostasis. Toxicol Appl Pharmacol 2019;381:114731. [PMID: 31449830 DOI: 10.1016/j.taap.2019.114731] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
69 Li L, Li D, Heyward S, Wang H. Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3β in Human Liver Cells. PLoS One 2016;11:e0150587. [PMID: 26930610 DOI: 10.1371/journal.pone.0150587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
70 Shizu R, Shindo S, Yoshida T, Numazawa S. MicroRNA-122 down-regulation is involved in phenobarbital-mediated activation of the constitutive androstane receptor. PLoS One 2012;7:e41291. [PMID: 22815988 DOI: 10.1371/journal.pone.0041291] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
71 Hebbani Nagarajappa S, Pandit S, Divanji M, Mariyanna B, Kumar P, Godavarthi A. Effect of Coleus forskohlii and its major constituents on cytochrome P450 induction. J Tradit Complement Med 2016;6:130-3. [PMID: 26870691 DOI: 10.1016/j.jtcme.2014.11.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
72 Sueyoshi T, Li L, Wang H, Moore R, Kodavanti PR, Lehmler HJ, Negishi M, Birnbaum LS. Flame retardant BDE-47 effectively activates nuclear receptor CAR in human primary hepatocytes. Toxicol Sci 2014;137:292-302. [PMID: 24218150 DOI: 10.1093/toxsci/kft243] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
73 Kumar R, Mota LC, Litoff EJ, Rooney JP, Boswell WT, Courter E, Henderson CM, Hernandez JP, Corton JC, Moore DD, Baldwin WS. Compensatory changes in CYP expression in three different toxicology mouse models: CAR-null, Cyp3a-null, and Cyp2b9/10/13-null mice. PLoS One 2017;12:e0174355. [PMID: 28350814 DOI: 10.1371/journal.pone.0174355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
74 Desta Z, El-Boraie A, Gong L, Somogyi AA, Lauschke VM, Dandara C, Klein K, Miller NA, Klein TE, Tyndale RF, Whirl-Carrillo M, Gaedigk A. PharmVar GeneFocus: CYP2B6. Clin Pharmacol Ther 2021;110:82-97. [PMID: 33448339 DOI: 10.1002/cpt.2166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
75 Niu RJ, Zheng QC, Zhang JL, Zhang HX. Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. J Mol Model 2011;17:2839-46. [PMID: 21301907 DOI: 10.1007/s00894-011-0970-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
76 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
77 McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8:371-382. [PMID: 22288606 DOI: 10.1517/17425255.2012.657626] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 15.5] [Reference Citation Analysis]
78 Helldén A, Madadi P. Pregnancy and pharmacogenomics in the context of drug metabolism and response. Pharmacogenomics 2013;14:1779-91. [PMID: 24192125 DOI: 10.2217/pgs.13.176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
79 Kim SJ, You J, Choi HG, Kim JA, Jee JG, Lee S. Selective inhibitory effects of machilin A isolated from Machilus thunbergii on human cytochrome P450 1A and 2B6. Phytomedicine 2015;22:615-20. [PMID: 26055126 DOI: 10.1016/j.phymed.2015.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
80 Cox PM, Bumpus NN. Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6. ChemMedChem 2016;11:2630-7. [PMID: 27860311 DOI: 10.1002/cmdc.201600519] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Musshoff F, Stamer UM, Madea B. Pharmacogenetics and forensic toxicology. Forensic Sci Int 2010;203:53-62. [PMID: 20828952 DOI: 10.1016/j.forsciint.2010.07.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
82 Yueh MF, Li T, Evans RM, Hammock B, Tukey RH. Triclocarban mediates induction of xenobiotic metabolism through activation of the constitutive androstane receptor and the estrogen receptor alpha. PLoS One 2012;7:e37705. [PMID: 22761658 DOI: 10.1371/journal.pone.0037705] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
83 Chen T, Tompkins LM, Li L, Li H, Kim G, Zheng Y, Wang H. A single amino acid controls the functional switch of human constitutive androstane receptor (CAR) 1 to the xenobiotic-sensitive splicing variant CAR3. J Pharmacol Exp Ther 2010;332:106-15. [PMID: 19820207 DOI: 10.1124/jpet.109.159210] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
84 Fraser EA, Henderson CJ, Wolf CR. Transcriptional Regulation of Cytochrome P450 Genes. Encyclopedia of Drug Metabolism and Interactions. Hoboken: John Wiley & Sons, Inc.; 2011. [DOI: 10.1002/9780470921920.edm008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Daly A. Pharmacogenetics and human genetic polymorphisms. Biochemical Journal 2010;429:435-49. [DOI: 10.1042/bj20100522] [Cited by in Crossref: 66] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
86 Saʼad Toyin A, Julius Olugbenga S, Rahman Ayodele B, Olusola Joseph O, Taibat Moji BO. Allele and Genotype Frequencies of Cytochrome P450 2B6 516G>T Single Nucleotide Polymorphism in HIV-Negative and HIV-Infected Adult Nigerian Populations. Am J Ther 2016;23:e1715-9. [PMID: 26938766 DOI: 10.1097/MJT.0000000000000340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
87 Haroun F, Al-shaar L, Habib RH, El-saghir N, Tfayli A, Bazarbachi A, Salem Z, Shamseddine A, Taher A, Cascorbi I, Zgheib NK. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. Cancer Chemother Pharmacol 2015;75:207-14. [DOI: 10.1007/s00280-014-2632-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
88 Pinheiro EA, Stika CS. Drugs in pregnancy: Pharmacologic and physiologic changes that affect clinical care. Semin Perinatol 2020;44:151221. [PMID: 32115202 DOI: 10.1016/j.semperi.2020.151221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
89 Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 2011;66:1332-9. [PMID: 21441248 DOI: 10.1093/jac/dkr087] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
90 Twist GP, Gaedigk R, Leeder JS, Gaedigk A. High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics 2013;14:913-22. [PMID: 23746185 DOI: 10.2217/pgs.13.66] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
91 Kenaan C, Shea EV, Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism. Drug Metab Dispos 2013;41:101-10. [PMID: 23043184 DOI: 10.1124/dmd.112.046094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
92 Ouchi K, Sugiyama K. Required propofol dose for anesthesia and time to emerge are affected by the use of antiepileptics: prospective cohort study. BMC Anesthesiol 2015;15:34. [PMID: 25788855 DOI: 10.1186/s12871-015-0006-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
93 Zemanová N, Lněničková K, Vavrečková M, Anzenbacherová E, Anzenbacher P, Zapletalová I, Hermanová P, Hudcovic T, Kozáková H, Jourová L. Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PLoS One 2021;16:e0259643. [PMID: 34752478 DOI: 10.1371/journal.pone.0259643] [Reference Citation Analysis]
94 Chalabianloo F, Westin AA, Skogvoll E, Bramness JG, Spigset O. Methadone serum concentrations and influencing factors: A naturalistic observational study. Psychopharmacology (Berl) 2019;236:3159-67. [PMID: 31139877 DOI: 10.1007/s00213-019-05277-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
95 Shah A, Gangwani MR, Chaudhari NS, Glazyrin A, Bhat HK, Kumar A. Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotox Res 2016;30:677-97. [PMID: 27364698 DOI: 10.1007/s12640-016-9646-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
96 Ahmad HI, Afzal G, Jamal A, Kiran S, Khan MA, Mehmood K, Kamran Z, Ahmed I, Ahmad S, Ahmad A, Hussain J, Almas S. In Silico Structural, Functional, and Phylogenetic Analysis of Cytochrome (CYPD) Protein Family. Biomed Res Int 2021;2021:5574789. [PMID: 34046497 DOI: 10.1155/2021/5574789] [Reference Citation Analysis]
97 Bracchi M, Stuart D, Castles R, Khoo S, Back D, Boffito M. Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. AIDS 2015;29:1585-92. [PMID: 26372268 DOI: 10.1097/QAD.0000000000000786] [Cited by in Crossref: 56] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
98 Kosaka M, Zhang D, Wong S, Yan Z. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition. Drug Metab Dispos 2020;48:655-61. [DOI: 10.1124/dmd.120.090878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
99 Dunnick JK, Morgan DL, Elmore SA, Gerrish K, Pandiri A, Ton TV, Shockley KR, Merrick BA. Tetrabromobisphenol A activates the hepatic interferon pathway in rats. Toxicol Lett 2017;266:32-41. [PMID: 27914987 DOI: 10.1016/j.toxlet.2016.11.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
100 Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 2013;38:152-63. [PMID: 23199531 DOI: 10.1503/jpn.120133] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 8.0] [Reference Citation Analysis]
101 Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW; ANRS 12154 Study Group. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics 2012;22:868-76. [PMID: 23104099 DOI: 10.1097/FPC.0b013e32835a5af2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
102 Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010;1187:184-207. [PMID: 20201854 DOI: 10.1111/j.1749-6632.2009.05275.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.4] [Reference Citation Analysis]
103 Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J; ANRS12154 Study Group. Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians. Antimicrob Agents Chemother 2017;61:e00733-17. [PMID: 28947469 DOI: 10.1128/AAC.00733-17] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
104 Zhou Q, Zheng Y. Comparative De Novo Transcriptome Analysis of Fertilized Ovules in Xanthoceras sorbifolium Uncovered a Pool of Genes Expressed Specifically or Preferentially in the Selfed Ovule That Are Potentially Involved in Late-Acting Self-Incompatibility. PLoS One 2015;10:e0140507. [PMID: 26485030 DOI: 10.1371/journal.pone.0140507] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
105 Chen J, Chen R. Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opinion on Drug Metabolism & Toxicology 2010;6:273-81. [DOI: 10.1517/17425250903505108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
106 Roberts SC, Bianco AC, Stapleton HM. Disruption of type 2 iodothyronine deiodinase activity in cultured human glial cells by polybrominated diphenyl ethers. Chem Res Toxicol 2015;28:1265-74. [PMID: 26004626 DOI: 10.1021/acs.chemrestox.5b00072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
107 Carvalho Henriques B, Yang EH, Lapetina D, Carr MS, Yavorskyy V, Hague J, Aitchison KJ. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? Front Genet 2020;11:491895. [PMID: 33363564 DOI: 10.3389/fgene.2020.491895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
108 Warry E, Hansen RJ, Gustafson DL, Lana SE. Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma. J Vet Intern Med 2011;25:903-8. [PMID: 21564295 DOI: 10.1111/j.1939-1676.2011.0730.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
109 Yoon HY, Cho YA, Yee J, Gwak HS. Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis. Sci Rep 2020;10:17390. [PMID: 33060725 DOI: 10.1038/s41598-020-74506-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Knights KM, Rowland A, Miners JO. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 2013;76:587-602. [PMID: 23362865 DOI: 10.1111/bcp.12086] [Cited by in Crossref: 23] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
111 Connarn JN, Flowers S, Kelly M, Luo R, Ward KM, Harrington G, Moncion I, Kamali M, McInnis M, Feng MR, Ellingrod V, Babiskin A, Zhang X, Sun D. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. AAPS J 2017;19:1513-22. [PMID: 28685396 DOI: 10.1208/s12248-017-0102-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
112 Jo JH, Kim S, Jeon TW, Jeong TC, Lee S. Investigation of the Regulatory Effects of Saccharin on Cytochrome P450s in Male ICR Mice. Toxicol Res 2017;33:25-30. [PMID: 28133510 DOI: 10.5487/TR.2017.33.1.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
113 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
114 Bernasconi C, Pelkonen O, Andersson TB, Strickland J, Wilk-Zasadna I, Asturiol D, Cole T, Liska R, Worth A, Müller-Vieira U, Richert L, Chesne C, Coecke S. Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study. Toxicol In Vitro 2019;60:212-28. [PMID: 31158489 DOI: 10.1016/j.tiv.2019.05.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
115 Yao S, Maghsoudlou D, Ambrosone CB. Breast Cancer Pharmacogenetics in the Era of Personalized Medicine. Curr Breast Cancer Rep 2012;4:271-81. [DOI: 10.1007/s12609-012-0088-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Hammond TG, Birdsall HH. Hepatocyte CYP2B6 Can Be Expressed in Cell Culture Systems by Exerting Physiological Levels of Shear: Implications for ADME Testing. J Toxicol 2017;2017:1907952. [PMID: 29081796 DOI: 10.1155/2017/1907952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
117 Zamek-gliszczynski MJ, Mohutsky MA, Rehmel JLF, Ke AB. Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk. Drug Metab Dispos 2014;42:1008-15. [DOI: 10.1124/dmd.114.057018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
118 Kim H, Lee Y, Kim V, Lee R, Bae SK, Kwak MK, Lee SH, Kim D. Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042. Toxicol Res 2020;36:195-201. [PMID: 32685423 DOI: 10.1007/s43188-019-00027-z] [Reference Citation Analysis]
119 Liu J, Shah MB, Zhang Q, Stout CD, Halpert JR, Wilderman PR. Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations. Biochemistry 2016;55:1997-2007. [PMID: 26982502 DOI: 10.1021/acs.biochem.5b01330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
120 Kang D, Geng T, Lian Y, Li Y, Ding G, Huang W, Ma S, Wang Z, Ma Z, Xiao W. Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method. Biomed Chromatogr 2017;31. [PMID: 27891633 DOI: 10.1002/bmc.3905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
121 Nakano M, Iwakami C, Fukami T, Nakajima M. Identification of miRNAs that regulate human CYP2B6 expression. Drug Metab Pharmacokinet 2021;38:100388. [PMID: 33872945 DOI: 10.1016/j.dmpk.2021.100388] [Reference Citation Analysis]
122 Chen JT, Wei L, Chen TL, Huang CJ, Chen RM. Regulation of cytochrome P450 gene expression by ketamine: a review. Expert Opin Drug Metab Toxicol 2018;14:709-20. [PMID: 29888644 DOI: 10.1080/17425255.2018.1487397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
123 Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. Antimicrob Agents Chemother 2016;60:6813-22. [PMID: 27600044 DOI: 10.1128/AAC.01000-16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
124 Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget 2017;8:20925-38. [PMID: 28178648 DOI: 10.18632/oncotarget.14995] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
125 Gay SC, Roberts AG, Halpert JR. Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem 2010;2:1451-68. [PMID: 21103389 DOI: 10.4155/fmc.10.229] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
126 Shizu R, Shindo S, Yoshida T, Numazawa S. Cross-talk between constitutive androstane receptor and hypoxia-inducible factor in the regulation of gene expression. Toxicol Lett 2013;219:143-50. [PMID: 23528251 DOI: 10.1016/j.toxlet.2013.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
127 Stiborová M, Poljaková J, Eckschlager T, Kizek R, Frei E. DNA and histone deacetylases as targets for neuroblastoma treatment. Interdiscip Toxicol 2010;3:47-52. [PMID: 21217872 DOI: 10.2478/v10102-010-0010-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
128 Kirischian N, Mcarthur AG, Jesuthasan C, Krattenmacher B, Wilson JY. Phylogenetic and Functional Analysis of the Vertebrate Cytochrome P450 2 Family. J Mol Evol 2011;72:56-71. [DOI: 10.1007/s00239-010-9402-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
129 Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011;36:1-16. [PMID: 21336516 DOI: 10.1007/s13318-011-0024-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 8.8] [Reference Citation Analysis]
130 Yuce-Artun N, Kose G, Suzen HS. Allele and genotype frequencies of CYP2B6 in a Turkish population. Mol Biol Rep 2014;41:3891-6. [PMID: 24562623 DOI: 10.1007/s11033-014-3256-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
131 Dietrich K, Baumgart J, Eshkind L, Reuter L, Gödtel-Armbrust U, Butt E, Musheev M, Marini F, More P, Grosser T, Niehrs C, Wojnowski L, Mathäs M. Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy. Drug Metab Dispos 2018;46:1827-35. [PMID: 30154105 DOI: 10.1124/dmd.118.082925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Sim J, Nam W, Lee D, Lee S, O H, Joo J, Liu K, Han JY, Ki SH, Jeong TC, Lee T, Lee S. Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. Arch Pharm Res 2015;38:725-33. [DOI: 10.1007/s12272-014-0443-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
133 Peters L, Demmel S, Pusch G, Buters J, Thormann W, Zielinski J, Leeb T, Mevissen M, Schmitz A. Equine cytochrome P450 2B6 — Genomic identification, expression and functional characterization with ketamine. Toxicology and Applied Pharmacology 2013;266:101-8. [DOI: 10.1016/j.taap.2012.10.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
134 Okamatsu G, Komatsu T, Ono Y, Inoue H, Uchide T, Onaga T, Endoh D, Kitazawa T, Hiraga T, Uno Y, Teraoka H. Characterization of feline cytochrome P450 2B6. Xenobiotica 2017;47:93-102. [DOI: 10.3109/00498254.2016.1145754] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
135 Radloff R, Gras A, Zanger UM, Masquelier C, Arumugam K, Karasi JC, Arendt V, Seguin-Devaux C, Klein K. Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools. Hum Mutat 2013;34:725-34. [PMID: 23418033 DOI: 10.1002/humu.22295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
136 Zakhariants AA, Burmistrova OA, Shkurnikov MY, Poloznikov AA, Sakharov DA. Development of a Specific Substrate-Inhibitor Panel (Liver-on-a-Chip) for Evaluation of Cytochrome P450 Activity. Bull Exp Biol Med 2016;162:170-4. [PMID: 27882460 DOI: 10.1007/s10517-016-3567-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
137 Gao L, Liu F, Yang L, Cheng L, Dai H, Tao R, Cao S, Wang D, Tang J. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity. Eur J Clin Pharmacol 2016;72:1205-13. [DOI: 10.1007/s00228-016-2095-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
138 Damiri B, Holle E, Yu X, Baldwin WS. Lentiviral-mediated RNAi knockdown yields a novel mouse model for studying Cyp2b function. Toxicol Sci 2012;125:368-81. [PMID: 22083726 DOI: 10.1093/toxsci/kfr309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
139 Fonseca F, de la Torre R, Díaz L, Pastor A, Cuyàs E, Pizarro N, Khymenets O, Farré M, Torrens M. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6:e19527. [PMID: 21589866 DOI: 10.1371/journal.pone.0019527] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
140 Zhong Q, Shi Z, Zhang L, Zhong R, Xia Z, Wang J, Wu H, Jiang Y, Sun E, Wei Y, Feng L, Zhang Z, Liu D, Song J, Jia X. The potential of Epimedium koreanum Nakai for herb–drug interaction. Journal of Pharmacy and Pharmacology 2017;69:1398-408. [DOI: 10.1111/jphp.12773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
141 Daraki A, Zachaki S, Koromila T, Diamantopoulou P, Pantelias GE, Sambani C, Aleporou V, Kollia P, Manola KN. The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities. PLoS One 2014;9:e88879. [PMID: 24586425 DOI: 10.1371/journal.pone.0088879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
142 Ma J, Feng Y, Jiang S, Li X. Altered cellular metabolism of HepG2 cells caused by microcystin-LR. Environmental Pollution 2017;225:610-9. [DOI: 10.1016/j.envpol.2017.03.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
143 Wang D, Wang H. Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors. Acta Pharm Sin B 2012;2. [PMID: 24349963 DOI: 10.1016/j.apsb.2012.02.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
144 Mourão AL, de Abreu FG, Fiegenbaum M. Impact of the Cytochrome P450 2B6 (CYP2B6) Gene Polymorphism c.516G>T (rs3745274) on Propofol Dose Variability. Eur J Drug Metab Pharmacokinet 2016;41:511-5. [PMID: 26141406 DOI: 10.1007/s13318-015-0289-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
145 Gao L, He Y, Tang J, Yin J, Huang Z, Liu F, Ouyang D, Chen X, Zhang W, Liu Z, Zhou H. Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. PLoS One 2013;8:e62489. [PMID: 23840296 DOI: 10.1371/journal.pone.0062489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
146 Lou D, Bao S, Li Y, Lin Q, Yang S, He J. Inhibitory Mechanisms of Myricetin on Human and Rat Liver Cytochrome P450 Enzymes. Eur J Drug Metab Pharmacokinet 2019;44:611-8. [DOI: 10.1007/s13318-019-00546-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
147 Siller-matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-karth G. Clinical implications of drug-drug interactions with P2Y 12 receptor inhibitors. J Thromb Haemost 2014;12:2-13. [DOI: 10.1111/jth.12445] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
148 Mittal B, Tulsyan S, Kumar S, Mittal RD, Agarwal G. Cytochrome P450 in Cancer Susceptibility and Treatment. Elsevier; 2015. pp. 77-139. [DOI: 10.1016/bs.acc.2015.06.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
149 Gadel S, Friedel C, Kharasch ED. Differences in Methadone Metabolism by CYP2B6 Variants. Drug Metab Dispos 2015;43:994-1001. [PMID: 25897175 DOI: 10.1124/dmd.115.064352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
150 Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine-Overview of the Molecular Mechanisms of Action. Int J Mol Sci 2021;22:1662. [PMID: 33562229 DOI: 10.3390/ijms22041662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLoS One 2020;15:e0229896. [PMID: 32155178 DOI: 10.1371/journal.pone.0229896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
152 Gates LA, Lu D, Peterson LA. Trapping of cis-2-butene-1,4-dial to measure furan metabolism in human liver microsomes by cytochrome P450 enzymes. Drug Metab Dispos 2012;40:596-601. [PMID: 22187484 DOI: 10.1124/dmd.111.043679] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
153 Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW; A5207 ACTG Study Team. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis 2013;208:662-71. [PMID: 23687222 DOI: 10.1093/infdis/jit223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
154 Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011;39:2329-37. [PMID: 21930825 DOI: 10.1124/dmd.111.038646] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
155 Bortell N, Basova L, Semenova S, Fox HS, Ravasi T, Marcondes MC. Astrocyte-specific overexpressed gene signatures in response to methamphetamine exposure in vitro. J Neuroinflammation 2017;14:49. [PMID: 28279172 DOI: 10.1186/s12974-017-0825-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
156 Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol 2012;74:1005-12. [PMID: 22471906 DOI: 10.1111/j.1365-2125.2012.04288.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
157 Li H, Ferguson SS, Wang H. Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation. Mol Pharmacol 2010;78:704-13. [PMID: 20624854 DOI: 10.1124/mol.110.065185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
158 Lv J, Hu L, Zhuo W, Zhang C, Zhou H, Fan L. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Pharmacogenetics and Genomics 2016;26:80-7. [DOI: 10.1097/fpc.0000000000000190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
159 Dickmann LJ, Isoherranen N. Quantitative Prediction of CYP2B6 Induction by Estradiol During Pregnancy: Potential Explanation for Increased Methadone Clearance During Pregnancy. Drug Metab Dispos 2013;41:270-4. [DOI: 10.1124/dmd.112.047118] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
160 Shah MB, Kufareva I, Pascual J, Zhang Q, Stout CD, Halpert JR. A structural snapshot of CYP2B4 in complex with paroxetine provides insights into ligand binding and clusters of conformational states. J Pharmacol Exp Ther 2013;346:113-20. [PMID: 23633618 DOI: 10.1124/jpet.113.204776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
161 Bueters R, Bael A, Gasthuys E, Chen C, Schreuder MF, Frazier KS. Ontogeny and Cross-species Comparison of Pathways Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Neonates (Review): Kidney. Drug Metab Dispos 2020;48:353-67. [DOI: 10.1124/dmd.119.089755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
162 Oh DA, Crean CS. Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects: Single-Dose Pharmacokinetics of Bupropion Hydrobromide. Clinical Pharmacology in Drug Development 2015;4:346-53. [DOI: 10.1002/cpdd.195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Imaishi H, Goto T. Effect of genetic polymorphism of human CYP2B6 on the metabolic activation of chlorpyrifos. Pestic Biochem Physiol 2018;144:42-8. [PMID: 29463407 DOI: 10.1016/j.pestbp.2017.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
164 Van Peer E, Jacobs F, Snoeys J, Van Houdt J, Pijpers I, Casteleyn C, Van Ginneken C, Van Cruchten S. In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs. Pharm Res 2017;34:750-64. [DOI: 10.1007/s11095-017-2101-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
165 Lam YF, Cavallari LH. Principles of Pharmacogenomics. Pharmacogenomics. Elsevier; 2013. pp. 1-44. [DOI: 10.1016/b978-0-12-391918-2.00001-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
166 Kis O, Sankaran-Walters S, Hoque MT, Walmsley SL, Dandekar S, Bendayan R. HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition. Antimicrob Agents Chemother 2016;60:2771-81. [PMID: 26902756 DOI: 10.1128/AAC.02278-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
167 Diethelm-Varela B, Ai Y, Liang D, Xue F. Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends. Curr Top Med Chem 2019;19:691-712. [PMID: 30931858 DOI: 10.2174/1568026619666190401100519] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
168 Gadel S, Crafford A, Regina K, Kharasch ED. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metab Dispos 2013;41:709-13. [PMID: 23298862 DOI: 10.1124/dmd.112.050625] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
169 Cook-Sather SD, Adamson PC, Li J, Hakonarson H. CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine! Anesthesiology 2016;125:1085-7. [PMID: 27763886 DOI: 10.1097/ALN.0000000000001399] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Chen H, Shen ZY, Xu W, Fan TY, Li J, Lu YF, Cheng ML, Liu J. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol 2014; 20(26): 8681-8690 [PMID: 25024626 DOI: 10.3748/wjg.v20.i26.8681] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
171 Zhou W, Mo Z, Xiao F, Dai W, Wang G, Zhou G, Zhang W, Chen B. microRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients. Platelets 2020;31:897-905. [DOI: 10.1080/09537104.2019.1696455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Tittle V, Bull L, Boffito M, Nwokolo N. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Clin Pharmacokinet 2015;54:23-34. [PMID: 25331712 DOI: 10.1007/s40262-014-0204-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
173 Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, Daali Y, Reny JL, Samer CF. Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clin Pharmacol Ther 2021;110:1358-67. [PMID: 34473836 DOI: 10.1002/cpt.2412] [Reference Citation Analysis]
174 Feng P, Liu Z. Complex gene expansion of the CYP2D gene subfamily. Ecol Evol 2018;8:11022-30. [PMID: 30519424 DOI: 10.1002/ece3.4568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
175 Latuga NM, Wahler RG. Very-High-Dose Methadone With Minimal Toxicity and Inadequate Pain Control in a Hospice Patient With Cancer. Journal of Pain & Palliative Care Pharmacotherapy 2013;27:143-9. [DOI: 10.3109/15360288.2013.786011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
176 Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H. Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group--An Industry Perspective. Drug Metabolism and Disposition 2016;44:1720-30. [DOI: 10.1124/dmd.116.071076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
177 Kharasch ED, Greenblatt DJ. Methadone Disposition: Implementing Lessons Learned. J Clin Pharmacol 2019;59:1044-8. [PMID: 31044453 DOI: 10.1002/jcph.1427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
178 Lind L, Ng E, Ingelsson E, Lindgren C, Salihovic S, van Bavel B, Mahajan A, Lampa E, Morris AP, Lind PM. Genetic and methylation variation in the CYP2B6 gene is related to circulating p,p'-dde levels in a population-based sample. Environ Int 2017;98:212-8. [PMID: 27839851 DOI: 10.1016/j.envint.2016.11.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
179 Abdullahi ST, Soyinka JO, Olagunju A, Bolarinwa RA, Olarewaju OJ, Bakare-Odunola MT, Winterberg M, Tarning J, Owen A, Khoo S. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. J Clin Pharmacol 2020;60:351-60. [PMID: 31549442 DOI: 10.1002/jcph.1527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Mączka W, Duda-Madej A, Górny A, Grabarczyk M, Wińska K. Can Eucalyptol Replace Antibiotics? Molecules 2021;26:4933. [PMID: 34443521 DOI: 10.3390/molecules26164933] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
181 Arab-Alameddine M, Décosterd LA, Buclin T, Telenti A, Csajka C. Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opin Drug Metab Toxicol. 2011;Epub ahead of print. [PMID: 21500966 DOI: 10.1517/17425255.2011.562891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
182 Oshio T, Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver. Xenobiotica 2019;49:265-9. [DOI: 10.1080/00498254.2018.1439204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
183 Wilderman PR, Shah MB, Jang HH, Stout CD, Halpert JR. Structural and thermodynamic basis of (+)-α-pinene binding to human cytochrome P450 2B6. J Am Chem Soc 2013;135:10433-40. [PMID: 23786449 DOI: 10.1021/ja403042k] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
184 Barber J, Russell MR, Rostami-hodjegan A, Achour B. Characterization of CYP2B6 K262R allelic variants by quantitative allele-specific proteomics using a QconCAT standard. Journal of Pharmaceutical and Biomedical Analysis 2020;178:112901. [DOI: 10.1016/j.jpba.2019.112901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
185 Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 2011;12:215-33. [DOI: 10.2217/pgs.10.171] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
186 Martinez MN, Antonovic L, Court M, Dacasto M, Fink-gremmels J, Kukanich B, Locuson C, Mealey K, Myers MJ, Trepanier L. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metabolism Reviews 2013;45:218-30. [DOI: 10.3109/03602532.2013.765445] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
187 Shah MB, Wilderman PR, Liu J, Jang HH, Zhang Q, Stout CD, Halpert JR. Structural and biophysical characterization of human cytochromes P450 2B6 and 2A6 bound to volatile hydrocarbons: analysis and comparison. Mol Pharmacol 2015;87:649-59. [PMID: 25585967 DOI: 10.1124/mol.114.097014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
188 Lynch C, Zhao J, Huang R, Xiao J, Li L, Heyward S, Xia M, Wang H. Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor. Sci Rep 2015;5:10405. [PMID: 25993555 DOI: 10.1038/srep10405] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
189 Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, Zhang Q, Stout CD, Halpert JR. Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution. Mol Pharmacol 2010;77:529-38. [PMID: 20061448 DOI: 10.1124/mol.109.062570] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]
190 Lo R, Burgoon L, Macpherson L, Ahmed S, Matthews J. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta 2010;1799:469-79. [PMID: 20079471 DOI: 10.1016/j.bbagrm.2010.01.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
191 Yang H, Wang H. Signaling control of the constitutive androstane receptor (CAR). Protein Cell 2014;5:113-23. [PMID: 24474196 DOI: 10.1007/s13238-013-0013-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
192 Restrepo JG, Martínez C, García-Agúndez A, Gaviria E, Laguna JJ, García-Martín E, Agúndez JA. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011;21:773-8. [PMID: 21886015 DOI: 10.1097/FPC.0b013e32834b3efc] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
193 Hamilton MC, Heintz MM, Pfohl M, Marques E, Ford L, Slitt AL, Baldwin WS. Increased toxicity and retention of perflourooctane sulfonate (PFOS) in humanized CYP2B6-Transgenic mice compared to Cyp2b-null mice is relieved by a high-fat diet (HFD). Food Chem Toxicol 2021;152:112175. [PMID: 33838175 DOI: 10.1016/j.fct.2021.112175] [Reference Citation Analysis]
194 Tu G, Zhan W, Sun Y, Wu J, Xiong Z, Liu J, Liu Y, Li H, Xia Y. CYP2B6 Polymorphisms Are Associated with Ischemic Stroke Risk in a Chinese Han Population. J Mol Neurosci 2020;70:1130-9. [PMID: 32307645 DOI: 10.1007/s12031-020-01520-z] [Reference Citation Analysis]
195 Benet M, Lahoz A, Guzmán C, Castell JV, Jover R. CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model. J Biol Chem 2010;285:28457-71. [PMID: 20622021 DOI: 10.1074/jbc.M110.118364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
196 Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene. Drug Metab Dispos 2011;39:2431-9. [PMID: 21930824 DOI: 10.1124/dmd.111.042176] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
197 Lo WS, Lim YP, Chen CC, Hsu CC, Souček P, Yun CH, Xie W, Ueng YF. A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Arch Toxicol 2012;86:1927-38. [PMID: 22790670 DOI: 10.1007/s00204-012-0902-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
198 Wang SC, Ho IK, Tsou HH, Tian JN, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, Su LW, Huang CL, Yang YH, Liu ML, Lin KM, Chen CY, Liu SC, Wu HY, Chan HW, Tsai MH, Lin PS, Liu YL. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011;31:463-9. [PMID: 21694616 DOI: 10.1097/JCP.0b013e318222b5dd] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
199 Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010;14:625-9. [PMID: 19897389 DOI: 10.1016/j.ejpain.2009.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
200 Damiri B, Baldwin WS. Cyp2b-Knockdown Mice Poorly Metabolize Corn Oil and Are Age-Dependent Obese. Lipids 2018;53:871-84. [PMID: 30421529 DOI: 10.1002/lipd.12095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
201 Tasnim F, Singh NH, Tan EKF, Xing J, Li H, Hissette S, Manesh S, Fulwood J, Gupta K, Ng CW, Xu S, Hill J, Yu H. Tethered primary hepatocyte spheroids on polystyrene multi-well plates for high-throughput drug safety testing. Sci Rep 2020;10:4768. [PMID: 32179810 DOI: 10.1038/s41598-020-61699-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
202 Frasco MA, Mack WJ, Van Den Berg D, Aouizerat BE, Anastos K, Cohen M, De Hovitz J, Golub ET, Greenblatt RM, Liu C. Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. AIDS. 2012;26:2097-2106. [PMID: 22951632 DOI: 10.1097/qad.0b013e3283593602] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
203 Wang Y, Xiang X, Wu SQ, Chen G, Zhang MM, Wang MG, Wang FJ, Sandford AJ, He JQ. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population. Infect Genet Evol 2017;51:198-202. [PMID: 28389387 DOI: 10.1016/j.meegid.2017.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
204 Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol 2018;153:196-204. [PMID: 29458047 DOI: 10.1016/j.bcp.2018.02.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
205 Michaud V, Bar-magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA, Shapiro TA. The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacol Rev 2012;64:803-33. [DOI: 10.1124/pr.111.005553] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
206 Lee Y, Park HG, Kim V, Cho MA, Kim H, Ho TH, Cho KS, Lee IS, Kim D. Inhibitory effect of α-terpinyl acetate on cytochrome P450 2B6 enzymatic activity. Chem Biol Interact 2018;289:90-7. [PMID: 29723517 DOI: 10.1016/j.cbi.2018.04.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
207 Liu Z, Li L, Wu H, Hu J, Ma J, Zhang QY, Ding X. Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo. Drug Metab Dispos 2015;43:208-16. [PMID: 25409894 DOI: 10.1124/dmd.114.061812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
208 Idda ML, Campesi I, Fiorito G, Vecchietti A, Urru SAM, Solinas MG, Franconi F, Floris M. Sex-Biased Expression of Pharmacogenes across Human Tissues. Biomolecules 2021;11:1206. [PMID: 34439872 DOI: 10.3390/biom11081206] [Reference Citation Analysis]
209 Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol 2009;609:88-95. [PMID: 19285975 DOI: 10.1016/j.ejphar.2009.03.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
210 Crane AL, Klein K, Olson JR. Bioactivation of chlorpyrifos by CYP2B6 variants. Xenobiotica 2012;42:1255-62. [PMID: 22775490 DOI: 10.3109/00498254.2012.702246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]